Back to Journals » Biologics: Targets and Therapy » Volume 6
Review
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
15,487 | Dovepress* | 11,607+ | 2,538 | 14,145 | |
PubMed Central* | 3,880 | 1,190 | 5,070 | ||
Totals | 15,487 | 3,728 | 19,215 | ||
*Since 25 September 2012 +Since July 2016 |
View citations on PubMed Central and Google Scholar